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Abstract
Characterizing changes in protein-protein interactions associated with sequence variants (e.g.
disease-associated mutations or splice forms) or following exposure to drugs, growth factors or
hormones is critical to understanding how protein complexes are built, localized and regulated.
Affinity purification (AP) coupled with mass spectrometry permits the analysis of protein
interactions under near-physiological conditions, yet monitoring interaction changes requires the
development of a robust and sensitive quantitative approach, especially for large-scale studies
where cost and time are major considerations. To this end, we have coupled AP to data-
independent mass spectrometric acquisition (SWATH), and implemented an automated data
extraction and statistical analysis pipeline to score modulated interactions. Here, we use AP-
SWATH to characterize changes in protein-protein interactions imparted by the HSP90 inhibitor
NVP-AUY922 or melanoma-associated mutations in the human kinase CDK4. We show that AP-
SWATH is a robust label-free approach to characterize such changes, and propose a scalable
pipeline for systems biology studies.
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Introduction
Protein-protein interactions (PPIs) are essential to cellular functions, and are attractive
therapeutic intervention targets1, 2. PPIs are also becoming increasingly recognized for their
potential in contributing to disease phenotypes induced by genetic variations, including
splice variants, allelic variants and point mutations3–6. Systematic assessment of the
consequences of sequence variation on protein-protein interactions by yeast two hybrid
(Y2H) revealed clear interaction changes associated with disease-associated mutants7.
However, limiting PPI screening to Y2H analysis generates results that do not easily capture
quantitative differences in interaction potential and work best to highlight interactions that
are lost rather than de novo interactions that may be gained via sequence variation.
Affinity purification coupled with mass spectrometry (AP-MS) can identify interactions in
near-physiological conditions, providing proper functional context to the studied protein
modules8. While many groups have employed AP-MS to identify static interactomes, very
few publications have focused on the identification of differential interactions; in all cases,
these studies have employed quantitative proteomics, with or without isotopes, to
discriminate between condition-specific interactions (reviewed in 9, 10). Notably, in these
studies, MS acquisition was performed in a data-dependent manner (DDA), where peptides
to be sequenced are selected based on the relative abundance of their precursor ion signals.
DDA introduces a degree of stochasticity in this process, which makes it very difficult to
conclude that a peptide or protein is truly absent in a given sample, especially for lower
abundance species11, 12. This is especially problematic for comparative quantification10.
In recent years, a different paradigm for MS-based quantification of proteins has gained
increased acceptance. Quantification using MS/MS (MS2) increases specificity and signal-
to-noise ratios as compared to MS1. This is the basis behind Selected/Multiple Reaction
Monitoring (S/MRM), which has been efficiently coupled to affinity purification, permitting
the detailed analysis of dynamic signaling modules13, 14. The utility of SRM in
quantification of AP samples is highlighted by its simplicity, accuracy and sensitivity15.
SRM quantification does not rely on the measured abundance of the precursor ion in MS1,
decreasing the chances for missing values in the dataset. However, SRM requires a
substantial investment in assay development for each peptide of interest16. Furthermore, the
list of analyzed peptide species is predetermined, precluding a posteriori reanalysis of this
type of data as new information becomes available, and the number of peptides quantified
per LC-MS/MS run is limited.
The advantages of quantification at the level of MS2 may also be harnessed in another type
of acquisition strategy, namely data-independent acquisition (DIA17; reviewed in 12). In
DIA, precursor ions are fragmented independently of their signal in MS1. A type of DIA
that is particularly promising for the analysis of AP samples is termed SWATH (Sequential
Window Acquisition of all THeoretical spectra)18. In SWATH, the entire useful mass range
is scanned in in a cycle time compatible with liquid chromatography using wide mass
isolation windows. All precursors in each window are fragmented, resulting in an MS2 map
of all compounds. A list of peptide fragment masses (e.g. acquired by a parallel DDA
experiment) is used to correlate MS2 peaks within the dataset to specific peptides allowing
quantification as in SRM data. The method benefits from many of the SRM attributes, such
as throughput and accuracy of quantification18, 19, and possesses a dynamic range
compatible with even the most complex interaction proteomics experiments (see
accompanying manuscript by Collins et al.). Here we present a complete experimental and
computational pipeline that couples affinity purification with SWATH quantification.
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Results
A pipeline for quantitative interactome monitoring
SWATH utilizes a fast-scanning QqTOF mass spectrometer20 to systematically fragment all
ions within a given m/z range. Eluting peptide precursor ions are isolated in sequential,
slightly overlapping windows of 25 amu (for 100 ms per window) and fragmented. The
composite MS/MS spectra for all co-eluting/co-isolated precursors are recorded as a
complete fragment ion map of the sample studied (Supplementary Fig. 1). As previously
reported18, quantification of SWATH data can be accomplished by targeted data extraction
using a list of fragment masses (see, e.g.18). To analyze our AP samples, each of the bait
samples was purified in biological replicates using FLAG magnetic beads, and peptides
were prepared by tryptic digestion. Each of the biological replicates was analyzed by
SWATH. We generated reference spectral libraries for targeted extraction by analyzing at
least one biological replicate for each of the groups of samples by Data-Dependent
Acquisition (DDA) (Fig. 1a, Supplementary Tables 1-2; Online Methods). The DDA
samples generated across a complete dataset were collectively searched using the
ProteinPilot™ software, and the MS2 spectra matching peptide sequences were used to
create a reference list of fragment masses for high confidence hits (see Methods for details).
This library was used to interrogate each SWATH run, enabling peptide quantification
across all SWATH samples, even if a given peptide was not identified in the matched DDA
run. The PeakView® SWATH Processing Micro App was used to identify the correct peak
group in a set of fragment chromatograms with peaks at the same retention time
(Supplementary Fig. 1c, 1e). Peak group scoring was similar to that described previously18
and used a combination of chromatographic correlation (related peaks should have the same
shape, width and retention time), mass error and additional predicted fragments ions; a
decoy strategy was used to select most likely peak groups for export and quantitative
analysis (Online Methods; Supplementary Fig. 1d).
Because of the amount of data generated by the SWATH approach and the goal of
minimizing manual processing, we developed a statistical method to calculate Fold Change
values and evaluate the confidence of these calculations. Normalization was performed by
calculating the most likely ratio between pairs of samples (see Methods), which generates a
scaling factor and metrics about the similarity of the samples and the quality of the
measurements. Normalization is applied stepwise, first to the samples that are expected to be
most similar (replicates) and then to the different sample groups (Figure 1b, 1c). The quality
metrics are combined with signal metrics, such as signal to noise ratio, and used as weights
in calculating Fold Change values using a strategy first described for the analysis of SRM
data for AP samples13, and referred to here as “Fold Change calculation”. With this
approach poor quality measurements are down-weighted, removing the need to manually
reject samples or measurements or to perform outlier rejection. Essentially, this statistical
tool evaluates the quality of each measurement using weights based on reproducibility
(results for each dataset used here are in Supplementary Fig. 2-7) and performs Fold Change
calculation of pairwise samples at the level of transitions, peptides, and proteins (see Online
Methods).
To determine whether the automated method yielded reproducible data, the variance for all
quantifiable peptides (with peak group FDR ≤ 1%; Supplementary Fig. 8) was measured on
a dataset consisting of cyclin dependent kinase CDK4 AP samples derived from three
biological replicates and analyzed in parallel by DDA and by SWATH (additionally, three
technical replicates were acquired for each biological replicate for SWATH). SWATH data
extraction led to quantification of 79% peptides within 20% CV (Fig. 2a), resulting in 87%
of proteins with ≤20% CV. These results were compared to MS1 area measurements
extracted using ProteinPilot software from the DDA data of the same replicates and used to
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determine both the level of stochasticity and variance in the measurement between samples.
5089 peptides were identified in any of the 3 DDA runs with an ID confidence ≥ 99%, but
only 2741 were common to all three DDA runs with an ID confidence ≥ 99% in at least one
of the replicates. These values highlight the issues of stochasticity associated with DDA
data. For comparison with the SWATH results, calculation of variance was performed only
on the 1320 high confidence peptides identified in all DDA runs and with ≤ 1% peak group
FDR in the SWATH data. As shown in Fig. 2b, SWATH had a higher proportion (82.1%
versus 74.5%) of peptides detected with CV ≤ 20% and also a smaller variance at the protein
level. More importantly, however, SWATH had the same reproducibility for extraction of
peptides targeted across all samples. From these studies, we conclude that our extraction and
normalization pipeline for SWATH data is reliable (also see Online Methods for additional
benchmarking measures), and we next benchmarked it on AP samples.
To test whether the automated pipeline could reproduce known interactions in complex AP
samples, we tested it for measuring interactions for well characterized baits, namely EIF4A2
and MEPCE, which we compared to a negative control (Green Fluorescent Protein fused to
a 3XFLAG tag). Here and throughout the manuscript, all proteins were stably expressed in
the Flp-In T-REx system, enabling recombinant protein expression to be driven in a
tetracycline-inducible manner from a single locus. N-terminal 3XFLAG tags permits
purification on FLAG M2 magnetic beads, followed by on-bead tryptic digestion as
previously described21. The resulting peptides were analyzed by DDA and SWATH in
triplicates. Following analysis by our automated pipeline, we observed that known
interaction partners of EIF4A2 and MEPCE showed large (≥ 2) fold change over the GFP
control (Fig. 2c; Supplementary Figs 9-11). In fact, the relative Fold Change values detected
for EIF4A2 (a component of the trimeric eIF4F complex) mirrored the known assembly of
the pre-initiation machinery in human cells22. The highest Fold Change values were
detected for the bait, followed by PDCD4 (a known negative regulator of EIF4A2 which
binds to the bait directly23) and the other components of eIF4F and the eIF3 complex (which
are tethered to EIF4A2 via direct association to eIF4G proteins). Next on the enrichment list
were many of the components of the 40S ribosomal subunit, which is recruited to EIF4A2
via the eIF3 complex; very few of the 60S ribosomal subunits were detected confidently
with ≥ 2-fold over the GFP control, consistent with the fact that this subunit only assembles
onto the 48S pre-initiation complex when translation is poised. Similarly, MEPCE, the
methylphosphate capping enzyme for 7SK RNAs, associated most strongly with
components of the 7SK small nuclear ribonucleoprotein complex24, followed by splicing
components and several components of the 60S ribosomal subunit which were in this case
enriched in preference to the 40S ribosomal components. In summary, after scoring based on
the comparison to negative control samples the AP-SWATH pipeline is robust, reproducible
and amenable to interactome mapping.
AP-SWATH rapidly identifies differential interactomes
We were interested here not only in scoring protein interactions over a negative control, but
importantly to systematically monitor interactome changes in pairs of samples (either
sequence variants, or drug-treated samples; Fig. 3a). We elected to study a well-described
series of sequence variants for the cyclin-dependent kinase CDK4 that have been identified
in melanoma patients25, 26. Structurally, mutation at Arg24 precludes association of CDK4
with a family of polypeptide inhibitors, the INK proteins (p15INK, p16INK, p18INK and
p19INK27 see Supplementary Table 1), resulting in derepressed CDK4 activity and
accelerated cellular proliferation7, 28. We first demonstrated that the sequence variants
behaved as expected, by performing AP-western with antibodies directed against known
endogenous partners. All recombinant proteins were expressed at similar levels to each other
and to the endogenous CDK4 (Fig. 3b). As expected, CDK4 wild-type, but not the two
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mutants (R24C and R24H) interacted with p18INK/CDKN2C (Fig. 3b). These samples –
and a negative control – were chosen to explore quantification by the AP-SWATH method.
Principal component analysis of the data from the four tested sample pairs revealed clear
separation of the negative controls from any of the baits (Fig. 4a). 17 proteins were enriched
at least two-fold in one of the three CDK4 baits: these were deemed CDK4 interactors (Fig.
4b; Supplementary Figs 12-14). To assess how these interactors were associating with either
of the two mutants in relation to the WT protein (clearly separated by PCA analysis; Fig.
4a), we implemented a stringent two-step filtering approach. Only CDK4 interactors (as per
Fig. 4b) were considered in an additional test to assess confidence of a change (up or down
in this case; we set an arbitrary threshold at 2-fold; Fig. 4c). When using the pipeline
described above to characterize interactions for the CDK4 proteins, we observed a number
of differentially regulated interactions between the WT and the two mutant proteins (R24C
and R24H). In contrast, the two mutants shared most interactions (Fig. 4d; Supplementary
Fig. 15). As expected, both mutants largely lost interactions with members of the INK
family of CDK inhibitors (5.7 to 9.8 fold reduction; Fig. 4d and Supplementary Figs 15-17;
see Online Methods for the description of the criteria for inclusion). However, we also
noticed a pronounced increase in the association of HSP90 proteins (HSP90AA1 and
HSP90AB1; ≥ 3.0 fold) and the CDC37 co-chaperone (≥ 3.9 fold) with the two mutant
proteins. In addition, the immunophilin FKBP51 (gene FKBP4) and to a lesser extent
HSP70 (gene HSPA8) were also significantly enriched in the mutants. To further cross-
validate these results, we performed an additional series of CDK4 affinity purification
coupled with iTRAQ labeling (Fig. 4d) and extracted abundance ratios for the 10 proteins
modulated in the R24 mutants as compared to the WT. The iTRAQ measurements revealed
modulation consistent with SWATH for these 10 proteins (Fig. 4d), though the variance
associated with iTRAQ measurements was considerably higher (Supplementary Fig. 18), at
least in part due to stochasticity between independent iTRAQ runs. The regulated
interactions with CDC37 and HSP90 were validated by AP-western analysis, confirming the
trends observed by AP-SWATH (Fig. 4e). Taken together, this indicated a higher propensity
of the mutant proteins to interact with HSP90 and suggested that the enriched interactors
may be recruited to CDK4 via interactions with HSP90 core components. These effects were
however not observed to the same extent with two other CDK4 mutants for which
interaction with the INK proteins is not modulated (N41S and S52N; Supplementary Figs
19-22), suggesting some degree of specificity in the recruitment of HSP90 to CDK4 mutants
at Arg24. In summary, the AP-SWATH method enabled confirmation of known regulated
interactions and quantification of the changes, and permitted the discovery of new
modulated interactions.
AP-SWATH can identify drug-regulated interactions
While increased interaction between CDK4 mutants and HSP90 has never been reported,
mutations in several other kinases (including EGFR and BRAF) increase their interaction
with CDC37 and HSP9029, 30. This was recapitulated here using a LUMIER approach (as
in 31; Fig. 5a; Supplementary Fig. 23). A model of addiction to HSP90 has been proposed
where mutant kinases become dependent on CDC37-HSP90 folding for stability and
activity32, offering a rationale for the use of HSP90 inhibitors that prevent the recruitment of
client proteins as a therapeutic avenue. Using AP-SWATH we thus assessed the
consequences on recruitment of CDC37 and HSP90 to the kinase constructs following
treatment with NVP-AUY922 (a potent HSP90 inhibitor currently undergoing clinical
trial33). We also reasoned that proteins that were displaced at the same time as CDC37 and
HSP90 may be dependent on the interaction with the core HSP90 network for their
interactions.
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As expected, treatment of the cells expressing CDK4 WT with the HSP90 inhibitor resulted
in marked dissociation of CDC37 and HSP90 (Fig. 5b, c; Supplementary Fig. 24-27). Many
of the proteins that showed increased association with the mutant proteins as compared to
WT were also affected in their interactions with the NVP-AUY922 treatment, indicating that
they are likely mediated by the CDC37/HSP90 bridge. Some other partners however,
including the chaperone HSP70 (genes HSPA1A and HSPA8) and some of its cofactors
(HOP (STIP1) and HIP (ST13))34, interacted more strongly with CDK4 WT in the presence
of the inhibitor, suggesting that not only are they not recruited via CDC37/HSP90 but that
they may compete with them for binding (Fig. 5c). Importantly, and in contrast to the report
that other mutant kinases show increased sensitivity for HSP90 inhibitors29, 30, 35, we found
that association of CDC37, HSP90 and FKBP4 to the mutant kinases was less affected than
that to the WT following inhibitor treatment (Fig. 5c). Since the mutants also bound
significantly more to these proteins in the absence of treatment (Fig. 4), this results in a
much larger net binding in the presence of the inhibitor. Similarly, HSP90 almost
completely dissociated from the WT CDK4 upon NVP-AUY922 treatment, whereas mutant
CDK4s still associated with significant amounts of the chaperone (Fig. 5d-e). This effect
was further explored by performing time-course and dose-dependence analysis of the
dissociation of the interactions. In all cases, association of the mutants with HSP90 and
CDC37 was preserved as compared to the WT kinase, with longer treatment or higher
dosages required for the dissociation of the CDK4 R24 mutants (Fig. 5f, g; Supplementary
Fig. 28). Taken together, these results indicate that tumors driven by CDK4 oncogenic
kinases may not benefit from treatment with HSP90 inhibitors, or may require higher
dosages to obtain the desired therapeutic results. Furthermore, our experiments set the stage
for analyzing other drug-regulated interactions, including for other kinase oncogenic
variants.
Discussion
Here we report the development of an efficient pipeline to quantitatively study changes in
interactomes in an unbiased and reproducible manner. Key aspects of the method are an
unbiased data independent acquisition method, SWATH, and the use of weighted statistics
to determine changes and associated confidence values. The latter is critical since it allows
automatic analysis of the large amounts of data that can be generated in these experiments.
We have also shown that AP-SWATH is able to identify true interaction partners by scoring
against negative control samples, and to rapidly identify interaction changes for disease-
associated mutations and or pharmacological treatment. As detailed in Supplementary Figs
29-32, the method is generally applicable, and we have implemented it to analyze the
consequences on the interactome of alternative splicing, this time using three splice variants
for another kinase, GRK631 (Supplementary discussion). In all the cases we analyzed in
more detail, the changes could be validated by AP-western analysis or iTRAQ quantitation.
As for all targeting methods, the key for SWATH quantification is the generation of a
spectral library. This can be provided from publicly-available resources (as in 18), but can
also be built for a particular set of proteins of interest. Here we generated a spectral library
from DDA data collected from the analysis of samples in each experimental set. We also
note that samples could – for example – be pooled for the DDA identification run, and
libraries could be built (as in 18) for extracting the quantitative information. As there are a
number of efforts to further understand the limits of DIA and SWATH and to evaluate ways
to build libraries, it is likely that new ways to analyze the data will become available. In fact,
this is a key strength of DIA: the data provides a permanent record of the whole sample,
enabling future reanalysis. In combination with proper data annotation (e.g. using LIMS
such as ProHits36), and deposition in public repositories (as we have done here with
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MassIVE), this should provide an important source of information for computational and
cancer biologists alike.
METHODS
Methods and any associated references are available in the online version of the paper.
ONLINE METHODS
Generation of stable cell lines and drug treatment
The vector pDEST-5'Triple-FLAG-pcDNA5-FRT-TO was constructed from the pcDNA5-
FRT-FLAG vector38 and pMX-pie-pDEST-3X-FLAG39 by first preparing a HindIII/XhoI
cassette from pMX-pie-pDEST-3X-FLAG by PCR using the following oligos: 5’
ccttggAAGCTTCCACCATGGACTACAAAGACCATGACGG and 3’
ggacttCTCGAGtcagACCACTTTGTACAAGAAAGCTGAAC. This cassette was then
subcloned into the pcDNA5-FRT-FLAG vector (previously digested with HindIII/XhoI).
Entry clones of wild-type and cancer-derived allelic series for the cyclin dependent kinase
CDK4 (c70t, g71a, a122g and g155a; all expressed in nucleotide base pair changes, resulting
in the expression of mutants R24C, R24H, N41S and S52N, respectively) were previously
described7. Three splice variants of the GPCR-coupled receptor kinase GRK6 (variants A, B
and C that differ only in their C-terminal extension; Supplementary Fig. 29a) were as
previously reported31. Each entry clone was shuffled into the destination vector
pDEST-5'Triple-FLAG-pcDNA5-FRT-TO through homologous recombination using LR
clonase II (Gateway system; Invitrogen). The resulting vectors were co-transfected with the
pOG44 recombinase in Flp-In T-REx HEK 293 (Invitrogen, grown in DMEM supplemented
with 5% FBS, 5% calf serum, 100 U/mL penicillin/streptomycin) using Lipofectamine
(Invitrogen) as per supplier instructions. pcDNA5-FLAG-MEPCE and pcDNA-FLAG-
EIF4A2 were as previously described38. Cells stably expressing the constructs were selected
in 200ug/mL hygromycin for approximately 2 weeks at which point cells colonies were
pooled and expanded in 150mm plates. Upon reaching approximately 70% confluence,
tetracycline was added to a final concentration of 200 ng/mL to cell media for 24 hours,
inducing the expression of the recombinant tagged protein. For experiments involving
HSP90 inhibition, the HSP90 inhibitor NVP-AUY92233 (20mM stock in DMSO) was added
for the indicated times and inhibitor concentrations to cells previously induced with
tetracycline for 24 hours.
Affinity purification for mass spectrometry and validation by immunoblotting
Affinity purification was performed as previously described21 with minor modifications.
Briefly, cells expressing FLAG-tagged proteins were washed with 10mL of PBS before
being scraped in PBS using a rubber spatula. Cells from two 150mm plates were pelleted by
centrifugation, the supernatant removed, frozen on dry ice and kept frozen at −80°C until
ready to be used. Cells were lysed by resuspension in 1:4 (pellet weight/volume) ratio of
lysis buffer (50mM HEPES-KOH (pH 8.0), 100mM KCl, 2mM EDTA, 0.1% NP40, 10%
glycerol, 1mM PMSF, 1mM DTT and protease inhibitor cocktail (Sigma-Aldrich; P8340;
1:500)) followed by two freeze/thaw cycles. The resulting cell extract was then clarified by
centrifugation at 20 800 rfc for 20 min (4°C) before transferring the supernatant to a fresh
tube. Affinity purifications were performed by incubating the cleared lysate with 30uL of
pre-washed magnetic M2 anti-FLAG beads (Sigma-Aldrich) for 2 hours at 4°C on a nutator.
Two washes with 1mL of lysis buffer were then performed followed by an additional wash
with 1mL of 20mM Tris-HCl pH8 2mM CaCl2. For mass spectrometry analysis, 7.5uL of
20mM Tris-HCl pH8 containing 750ng of trypsin (Sigma-Aldrich) was added to the washed
beads and incubated at 37°C for approximately 15 hours. The next morning, the tubes were
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quickly centrifuged, the beads magnetized and the partially digested sample transferred to a
fresh tube before addition of an extra 2.5uL of 20mM Tris-HCl pH8 containing 250ng of
trypsin. The samples were incubated for 3 hours at 37°C before addition of 1uL of 50%
formic acid. The samples were stored at -80°C until analysis. For Western blot analysis, the
beads were resuspended in 2X Laemmli sample buffer, boiled for 5 minutes and the samples
transferred to fresh tubes. Proteins were separated by SDS-PAGE, and transferred onto
nitrocellulose membranes. For CDK4, the membranes were blocked in TBS containing 5
mg/mL non-fat milk and 1% Tween 20 for 1 hour at room temperature. Blots were treated
with primary and secondary antibodies as described in Supplementary Table 3: detection
was performed by chemiluminescence detection with the LumiGLO reagent (Cell Signaling
Technology; #7003; 1:20) on film. For GRK6, the membranes were blocked in 5% non-fat
milk for 30 minutes at room temperature, then treated with primary antibodies overnight,
followed by incubation for 1.5 hours with IRDye® 800CW anti-mouse and IRDye® 680
anti-rabbit secondary antibodies (shown in Supplementary Table 3). The GRK6 membranes
were then visualized by direct fluorescence scanning with a Li-Cor Odyssey Imager. HSP90
bands were quantified with Li-Cor Odyssey software.
LUMIER analysis
LUMIER analysis1 was performed essentially as described in31. Briefly, wild type kinases
and indicated mutants C-terminally tagged with 3X FLAG and V5 tags were transiently
transfected in a 96 well format into 293T cells stably expressing Renilla luciferase-tagged
HSP90beta (HSP90AB). After passive lysis (in 50 mM HEPES-KOH pH 7.9, 150 mM NaCl,
20 mM Na2MoO4, 2 mM EDTA, 5% glycerol, 0.5% Triton X-100, supplemented with
protease and phosphatase inhibitors), the lysate was transferred into 384 well plates
precoated with anti-FLAG M2 (Sigma-Aldrich) and incubated for 3 hours, followed by
extensive washing and reaction with Gaussia FLEX luciferase kit (New England Biolabs).
Subsequently, the levels of the FLAG-tagged bait were detected by ELISA using HRP-
conjugated anti-FLAG antibody. Data analysis was performed as described in 31.
Description of the datasets used here
This manuscript contains several datasets, organized in groups as detailed in Supplementary
Table 2. For Fig. 1 and 2a and b, the CDK4 WT runs from a set containing 9 SWATH
replicates (3 biological×3 technical) and 3 DDA replicates (3 biological) was employed
(group 5 in the Supplementary Table). For Fig. 2c, the dataset consisted of three biological
replicates of each of the following: MEPCE, EIF4A2 and a GFP negative control (group 6).
Fig. 4a and b employed 2 biological replicates each of DMSO-treated CDK4 WT, R24C,
R24H and an empty vector negative control (partial selection from group 3). Fig. 4d (left)
employed three biological replicates for the CDK4 WT, R24C and R24H mutants from
group 1 while the right panel was from the iTRAQ dataset in group 7. Fig. 5 used the entire
HSP90 inhibitor dataset (group 3). Datasets groups 2 and 4 were used for Supplementary
Figures.
iTRAQ labeling
For validation of SWATH-MS results, an extra set of triplicate purifications of CDK4
samples were processed as described above except that Hepes buffer was substituted for Tris
buffer during trypsin digestion, and samples were not acidified following tryptic digestion.
Rather, the peptides were dried in a speedvac without heat and subsequently resuspended in
5 µL of iTRAQ dissolution buffer (as per the manufacturer, AB-SCIEX, protocol). 20 µL of
the appropriate iTRAQ reagent (from a stock solution of 50 µL in isopropanol) was added to
each sample. Samples were labeled as follow: 3XFLAG-GFP control (115), 3XFLAG
CDK4 WT (116), 3XFLAG-CDK4 R24C (118) and 3XFLAG-CDK4 R24H (119). After
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completion of the labeling reaction (2 hours at room temperature), equal volumes of samples
from individual biological replicates were mixed and evaporated to dryness in a speedvac.
The dry peptides were resolubilized in 5% formic acid solution in water and one eighth of
the labeled peptides was used per MS analysis. This corresponded to loading twice as much
peptides (in relation to the starting material) on the column as in the SWATH experiments.
Mass spectrometry data acquisition
Samples were analyzed on an AB SCIEX 5600 TripleTOF in two phases: data dependent
acquisition (DDA) was followed by SWATH acquisition on the same sample, using the
same gradient conditions and the same amounts of sample (in most cases; detailed in
Supplementary Table 2, DDA acquisition was performed on a single biological replicate,
except for datasets 5 and 6 for which three DDA runs per bait were generated). For DDA, a
quarter of the volume of the digested sample was analyzed on a 5600 TripleTOF, using a
Nanoflex cHiPLC system at 200 nL/min (Eksigent ChromXP C18 3 µm×75 µm×15 cm
column chip) or a home-packed emitter column (Dr. Maish Reprosil C18 3 µm×75 µm×10
cm) as indicated in Supplementary Table 2. Buffer A was 0.1% formic acid in water; buffer
B was 0.1% formic acid in ACN. The HPLC delivered an acetonitrile gradient over 120 min
(2-35% buffer B over 85 min, 40-60% buffer B over 5 min, 60-90% buffer B over 5 min,
hold buffer B at 90% 8 min, and return to 2% B at 105min). The DDA parameters for
acquisition on the TripleTOF 5600 were 1 MS scan (250ms; mass range 400-1250) followed
by a) up to 50 MS/MS scans (50ms each) b) up to 20 MS/MS scans (100ms each) or c) up to
10 MS/MS scans (100ms each) as indicated in Supplementary Table 2. Candidate ions
between 2-5 charge state and above a minimum threshold of 200 counts per second were
isolated using a window of 0.7 amu. Previous candidate ions were dynamically excluded for
20 sec with a 50 mDa window. The SWATH setup was essentially as in Gillet et al.18, using
the same chromatographic conditions as the DDA run described above, a 50 ms MS1 scan,
followed by 32×25 amu isolation windows covering the mass range of 400 to 1250 amu
(cycle time of 3.25 sec); an overlap of 1 Da between SWATH was preselected. The collision
energy for each window was set independently as defined by CE = 0.06 * m/z + 4, where m/
z is the center of the each window, with a spread of 15eV performed linearly across the
accumulation time. For the GRK6 experiments, the retention times were realigned based on
landmark peptides to correct for the different chromatographic systems employed in this
experimental set. The iTRAQ samples were acquired by DDA as described above (with the
iTRAQ CE option applied), using a packed tip emitter system with direct injection, and up
to 20 MS/MS scans were performed in each cycle.
Data Dependent Acquisition processing for targeted extraction
Data generated by DDA was searched against the human complement of the Uniprot release
8.8 database containing 40476 sequences using ProteinPilot™ AB SCIEX Beta 4.1.46,
revision 460. Searches were performed using ProteinPilot’s standard “rapid search”
parameter space that includes common modifications as part of the search. The search is
undertaken using the Paragon search engine (v 4.0.0.0). The specific nature of this search
engine and its mode of operation are described elsewhere40. Raw data for each experimental
set were searched in a single batch (the description of the files is in Supplementary Table 2)
to create a results file that was subsequently used for library generation.
Library generation
For each set of experiments (defined as per Supplementary Table 2), a specific library of
precursor masses and fragment ions was created and used for subsequent SWATH
processing. ProteinPilot result files were processed to extract matched peptide IDs and the
matched ions from the original input spectra. The matched spectra were filtered to produce a
list of parent masses and fragment masses and intensities to be used for SWATH processing
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Filtering removed peptide redundancy and identified the optimal spectrum for each peptide
according to the following scheme: 1) Spectra were grouped based on unique peptide
identification; 2) The grouped spectra were ranked based on identification confidence in
ProteinPilot; 3) The highest confidence identification closest to the LC parent ion peak apex
was selected (The chromatographic peak apex is estimated by ProteinPilot and is exported as
the intensity of the peak); 4) The highest ranked spectra were then reinterpreted and y and b-
ions identified; 5) A library entry was made from the y and b-ions for each top ranked
unique peptide spectrum. No attempt was made to generate a consensus spectrum from all
identifications of each peptide. The data within this library contained modified forms as well
as peptides which were shared between different protein isoforms.
SWATH data file processing
Prior to data processing, peptides were selected automatically from the library using the
following decision tree: 1) The extracted results from the ProteinPilot results file contains all
identified unique peptides for a specific targeted protein. These unique peptides were ranked
by the intensity of the MS1 precursor ion from the DDA analysis as estimated by the
ProteinPilot software; 2) Peptides which contained modifications and or were shared
between different protein entries / isoforms were excluded from selection; 3) Peptides which
were represented by multiple charge states in the list were collapsed to charge state which
had the most intense precursor ion in the DDA data. Up to 15 peptides were chosen per
protein and SWATH quantitation was attempted for all proteins in library files that were
identified below 1% FDR from Protein Pilot searches.
Target fragment ions, up to a number specified by the user and typically 4 or 5, were
automatically selected as follows: 1) Fragment ions for a selected peptide were ranked based
on ion intensity; 2) Ions higher in m/z than the y4 fragment ion for each selected peptide
were ranked highest; 3) Ions within the SWATH isolation window were excluded from
selection; 4) If insufficient target ions were found, ions lower than y4 but outside of the
SWATH window were chosen; 5) If there were still insufficient ions then fragment ions
from within the SWATH window region were chosen. Avoiding ions within the SWATH
window as much as possible decreases potential interferences from unfragmented precursor
ions.
The specifics of the scoring for the different peak groups will be described elsewhere (R.A.
and S.T, unpublished). In essence: 1) The fragment ions for each peptide were used to
generate extracted ion chromatograms (XIC) from the SWATH experiment which contained
the parent m/z; 2) Peaks identified in the different XICs were aligned by the peak apex
retention time and peaks which aligned across the different XICs were marked as potential
candidate peak groups; 3) For each candidate peak group on list, the overlap of the different
XIC peaks was evaluated, since related fragment ions should have the same peak width, and
those which did not have well correlated peak widths were removed from the candidate list.
Overlap was assessed by using the half-height width of the most intense fragment peak to
define a time window and verifying that the apex value of the other fragments was within
the window; 4) All the remaining peak groups were scored based on the closeness to the
expected retention time for the eluting component determined from the DDA data acquired
using the same chromatographic system; 5) The MS/MS spectra for the peak apex of each of
the remaining peak group candidates were extracted; 6) The extracted spectra were scored
based on the isotopic state of the individual ions extracted in the MS/MS spectra. Those
peak groups which contained measurements extracted from 13C isotopes were scored lower.
7) The MS/MS spectra were also scored based on the mass accuracy (both absolute and
median accuracy) of the extracted peaks. 6) The individual peak group scores were a linear
combination of all sub-scores and the peak group with the best score was taken forward.
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Determination of a robust peak extraction cutoff
To select the peak group confidence threshold for automated extraction, a method based on
mProphet41 was used to determine the false detection of peak groups. In essence, each
peptide had both a forward and a reverse (decoy) sequence extracted and the decoy sequence
scores were used to generate a median score value for the retention time region of each
forward sequence. This median score was used to normalize the score values and generate a
recomputed score that was ranked. As this ranked score list contains both forward and
reverse sequences, standard methods for determining false positive results can be used.
Here, we used data from the CDK4 WT dataset (group 5) to evaluate the impact of varying
FDR threshold selection on the CV values and the final Fold Change calculations. As shown
in Supplementary Figure 8a, the % peptides with CV values ≤ 20% were strongly impacted
by reducing the FDR stringency for peak extraction, consistent with the fact that FDR
thresholding properly acts to reduce noise. Surprisingly, however, initial FDR selection had
only a minimal impact on the final results of the Fold Change calculations (see below for
Methods), suggesting that robustness is built into the normalization process that weights
down the “bad” fragments/peptides (Supplementary Figure 8c). Despite this robustness (the
final list of the proteins passing the Fold Change confidence thresholds in this study was
virtually unaffected by extracting at 1% FDR or 10% FDR), for some proteins there was a
clear negative effect on the confidence scores associated with the 10% FDR extraction
(Supplementary Figure 8d). Therefore, we elected to use a consistent 1% extraction FDR
threshold for all the analyses performed in the main text.
Extraction of MS1 and comparative CV analyses
MS1 intensities for identified peptides were extracted directly from the ProteinPilot results
by exporting the ProteinPilot group files as a peptide summary table that includes the
expected precursor intensity. DDA peptides were filtered as follows: 1) the peptides should
be in common to all 3 DDA runs (otherwise, the missing value(s) drastically increases the
variance); 2) the peptides should have been identified with ID confidence ≥ 99% in at least
one of the three runs; 3) all peptides, including modified peptides, are considered; 4) each
charge state is considered as a separate instance for quantification; 5) instances of the same
peptide (with same charge) are considered the same peptides if they are within +/- 5 min
retention time window. This set of criteria led to 2741 common peptides, including different
charge state and modifications.
To best compare the MS1-DDA variance to that of SWATH, we used a subset of these
peptides that were deemed most reproducible (unmodified and present in only one protein)
and also detected in the SWATH analysis of the most similar samples, i.e. the DDA run and
the first SWATH analysis for each replicate. The SWATH data was restricted to those
peptides which had a FDR ≤ 1% in at least 2 samples (note that we are only attempting to
quantify the top 400 proteins in this analysis) and this list was merged with the DDA
peptides to identify common peptides and remove modified peptides. The resulting list
contains 1320 common peptides which were used to evaluate the CV values for the SWATH
and the DDA-MS1 measurements.
iTRAQ data analysis
iTRAQ data was analyzed using ProteinPilot 4.2, and the default ProGroup algorithm
iTRAQ processing parameters were used. After a rapid search against Uniprot protein
iTRAQ ratios were exported and standard deviations calculated across the replicate data
sets. To generate the Supplementary Fig. 18, quantitative information for proteins used in
the SWATH measurements were extracted, alongside their standard deviation.
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Determination of signal quality metrics
A signal quality value was determined for all raw data extracted. For the purpose of this
study the area of the peak was used as surrogate value for the signal-to-noise. The values for
each transition were normalized to a scale of 0 to 1.0 where a value of 1.0 corresponded to
an intensity of greater than 10e5. A sigmoidal distribution was used and the inflection point
of the curve was set to a value of 10e4. The signal quality metric is used during the fold
change determination of the peptides and proteins.
Normalization of peak area data
In a previous study13 which used SRM to monitor the changes in the GRB2 interactome
induced by stimulation or drug treatment, we normalized all data to the expression of the
GRB2 bait itself. This was possible as a single cell line was used for all studies and GRB2
levels were invariant across all conditions. Here, by contrast, we profiled the interactions
established by bait proteins expressed in independent cell lines. Though a major strength of
the expression system that we used is that the different alleles are expressed at a similar
level, there are small variations in expression levels that preclude normalization to the bait
level (when we did this analysis, proteins that non-specifically interacted with the affinity
matrix tended to be identified as varying). We and others have previously realized that many
of the proteins detected in AP-MS are interacting non-specifically with the affinity matrix,
but that these interactions were reproducibly detected, both qualitatively and
quantitatively37. With this knowledge, we therefore selected to use a normalization method
that is independent of the bait expression. As defined in13, the identification of features for
the normalization of data is critical. In this study we used features which had intensity
greater than 3000 (peak area) for normalization by a method similar to42 but modified since
mass spectrometry intensity data is linearly dependent on the amount of material present.
The same normalization scheme was used for each experiment set. The procedure starts by
examining the measurement ratios in biological replicates as follows: 1) The ratio between
the measurements for each feature in each pair of replicates is determined; 2) The ratios are
represented as a histogram and the delta of the most likely ratio to the zero point is taken for
each sample comparison (Fig. 1b). These values represent the sample differences and are
used for normalization of the data as described below; 3) The width of the ratio histogram is
determined and is used as an indication of pairwise sample similarity. Here a narrow
histogram will represent a good similarity between the different samples; 4) Measurement
reproducibility is also determined from the histogram as the distance of the feature ratio to
the peak apex of the histogram. Fig. 1c, top panel, shows the ratio histograms for all samples
compared to one WT sample prior to normalization.
The first stage of normalization adjusts the values for a set of replicates (here, for example,
biological replicates for the CDK4 WT samples are adjusted separately from the CDK4
R24C or R24H) since these values should be most similar. For each set, the best sample, as
measured by overall reproducibility, is determined and the values for all other samples are
adjusted using the appropriate apex ratio. The result of this intermediate normalization step
is represented by the middle panel in Fig. 1c, which shows the resulting ratio histograms and
indicates that replicates are now very similar. This data – referred to as the “biological
sample normalized data” - is then used to normalize between different experiments.
The second stage is normalization between the different experiment conditions, e.g. wild
type and a selected mutant, using the output from stage 1. These data were processed as
described above to determine the normalization factor for each experimental condition that
were applied to the “biological sample normalized data” generating the final “experimental
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normalized data”. The final result is represented in Fig. 1c, bottom, which shows that the
apex ratio between all samples is now unity.
Selection of the normalization method
The method used for normalization of the data (Most Likely Ratio Normalization, MLR)
was compared to other recognized methods of data normalization, including Total Area
Sums (TAS), and normalization to bait protein. TAS is performed by summing the responses
for each sample and then determining a ratio of each sample to the largest sum. This ratio is
used as a normalization factor for each sample. When normalizing to a bait protein, the
responses for the bait proteins are summed, and then the median ratio between the peptides
determined and this value is used to normalize all other measurements in each sample.
Supplementary Figure 33a shows the differences on the resulting PCA analysis between
sample grouping using TAS, normalization to the bait protein, and MLR for an experimental
dataset from triplicate analyses of three bait proteins where one replicate for two of the baits
had a much lower overall intensity. While the normalization to the bait clearly fails in this
case, there was an improvement in obtaining separation from using MLR over TAS. This
was most obvious when visualizing the ratio histograms after normalization (Supplementary
Figure 33b). As the primary aim of normalization is to minimize experimental variance,
balancing the ratio histograms is ensures that the variance has been minimized. The variance
of the samples is defined as the range of the peak apexes of the ratio histograms. Here, the
issues associated with the normalization to the bait protein (significant sample variance even
after normalization) are clearly depicted. While the TAS approach minimized this variance
between samples, the two outliers (intensity-wise) were still unaligned. By contrast, MLR
was successful at minimizing the variance, even for these samples with a poor intensity
response.
Note that in terms of the Fold Change determination, while normalization of the data to the
bait protein makes sense if the bait protein itself is expected to be a constant value (this was
in fact the method we used for the analysis of the SRM data in a previous publication13),
even small variations in the abundance of the bait protein across the samples strongly
affected the results (essentially, boosting all contaminant proteins in the samples in which
the bait was expressed to a lesser extent). Here, as seen in the western blots in Fig. 3b and 4e
(and accompanying quantitative mass spectrometry analysis), though the WT and mutants
CDK proteins were expressed at similar levels, these levels were not identical (the WT was
expressed to a higher level than the mutants). This prevented us from using the bait
normalization which we had previously employed; MLR was not impacted by these
differences.
Determination of fold change of values
All of the raw data collected was used to provide an input to the fold change determinations.
In essence the fold change of the protein was determined using the method reported in13.
Data after normalization – experimental normalized data - is used for the fold change
determination. This data is treated in the following manner: 1) For each set of biological
replicates a table of weighted average areas is determined using the transition reproducibility
values determined during normalization – “weighted area response”; 2) Weighted analysis
of variance is used to determine the likelihood of difference between the experimental test
conditions. The output is in essence a p-value as if a t-test was performed between the
different experiments but the use of weighted values better accounts for poor quality values
in the data being processed; 3) The “signal quality values” and “analysis of variance values”
(from step 2) are used to determine the peptide fold change values using a weighted average
fold change calculation; 4) A peptide signal quality table is determined from the transition
signal quality table by calculating the median signal quality for each set of transitions; 5)
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The peptide variance is determined by calculating the summed weighted average for the
transitions analysis of variance using the signal quality table as the weighting factor for the
individual transitions; 6) A protein fold change value is determined as described in Bisson et
al.13, with a slight modification that the protein value is again a weighted average using both
the peptide signal quality (step 4) and also the peptide variance (step 5) values as weights.
As described before, the output of this fold change determination is a fold change up and
down for each protein and a confidence value as determined from the peptide variance and
the peptide signal quality values.
All calculations were performed in MATLAB 2012 by executing custom coded algorithms
and data exported either in figure format or as text.
Determination of data quality metrics
Data quality is determined for the transitions, peptides and proteins and used to reject lower
quality values from subsequent processing and display: 1) The transition quality matrix is
determined by taking the maximum median value of the data in the transition reproducibility
matrix as determined in the normalization of the data; 2) The peptide quality matrix is
determined by taking median value for the transition quality values; 3) The protein quality is
determined from the median of the individual peptide quality values.
Filter parameters for data visualization and figure generation
Data represented in all figures was generated using a series of custom algorithms executed
within the MATLAB environment. The output from these scripts were figures and tables
representing the fold change and corresponding confidence values.
Although data was filtered primarily using a confidence threshold of ≥ 0.75, we also
required a minimum log10 (fold change) value of 0.2. This latter value is based on
distributions of pairwise fold change values for all measurements with confidence values
less than ≤ 0.75 (i.e. most likely not changing) in the initial CDK4 mutant experiment which
showed that ca. 95% of the log10 (fold change) values were less than 0.2. Further, to ensure
that each protein is represented by high quality measurements, we required at least 2
peptides per protein and used signal quality and reproducibility thresholds of 0.15
(determined from the appropriate histograms).
For the data presented in the main text figures, an additional filtering scheme, based on the
Fold Change calculations, was applied to ensure that only specific interactors for a bait are
considered as “potentially modulated interactors”. Essentially, we applied two criteria: 1) the
prey protein must have passed the confidence and Fold Change thresholds as defined above
and be up-regulated in comparison to a set of negative control samples processed in parallel
(we consider any proteins passing the thresholds across the entire set of baits to be tested a
“specific interactor” for the bait); 2) pairwise comparisons between sequence variants and/or
drug treatments are then performed, only considering the “specific interactors”, and the
same thresholds (this time, up or down) are applied. Data resulting only from the second
step (meaning without first ensuring that the proteins analyzed are non-contaminants) can be
found in Supplementary Figs 20-22 and 30-32; 34-39). However, since we did not use the
two-step filtering process for the Supplemental data presented for additional mutants of
CDK4 and splice variants of GRK6, these values should be interpreted with caution.
The layout of the figures was also generated in MATLAB and annotated in Illustrator: In the
case of the complete dataset representation for each experiment set, the rank is based on the
global view where proteins are ranked by decreasing confidence of fold change across any
two pairs.
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The figures presented in the main text utilize the same filtering criteria and cutoffs and
represent the Fold Change data as a heat-map generated (increasing ratios) using
MultiExperiment Viewer version 4.8.1 (MeV; http://www.tm4.org/mev/).
Access to data
All mass spectrometry data as well as each of the steps of the analysis can be found at
prohits-web. lunenfeld.ca. Raw mass spectrometry files were also deposited in the MassIVE
repository, housed in the Center for Computational Mass Spectrometry at UCSD (http://
massive.ucsd.edu/ProteoSAFe/datasets.jsp); see Supplementary Table 4 for IDs and links to
each of the datasets.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
AP-SWATH pipeline. (a) MS analysis pipeline: each sample is processed separately for
DDA and SWATH, and the spectral library built from all DDA runs within an experimental
set is used to retrieve quantitative information from each of the SWATH runs. A series of
tools are used to automatically match the DDA and SWATH spectra, extract quantitative
information, normalize the transitions, peptides and proteins, and determine the Fold Change
differences between samples, and the confidence on the Fold Change. (b) Schematic of the
parameters used for normalization. Intensity ratio histograms are generated between pairs of
samples, and a number of metrics are derived. (c) Effects of the normalization steps on the
area ratio histograms demonstrated for a dataset consisting of 9 samples derived from CDK4
WT, 9 from CDK4 R24C and nine from CDK4 R24H. The top panel shows the ratio
histograms before normalization; the middle panel, after normalization based on
experimental types (here biological replicates); and the bottom panel shows the final results
after normalization of the experimental bias.
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Figure 2.
AP-SWATH for scoring protein interactions. (a) Reproducibility metrics for the SWATH
extraction at 1% FDR in relation to the binned % CV values; the upper boundary is
indicated. (b) Reproducibility metrics for the common peptides identified in all DDA
experiments and extracted from SWATH data with 1% FDR. The numbers of peptides and
proteins identified/quantified within the %CV indicated are listed, and the overall
percentages of peptides/protein within the 20% CV interval are indicated. (c) Fold Change
calculation results for the FLAG-EIF4A2 bait in relation to a negative control, FLAG-GFP
(left), and for FLAG-MEPCE in relation to FLAG-GFP (right). The proteins that changed ≥
2-fold with a confidence ≥ 0.75 are displayed: increased proteins (yellow scale) are specific
to the bait in relation to the control while the decreased proteins (blue scale) are more
abundant in the negative control samples, and likely contaminants (these tend to be enriched
in the Contaminant Repository for Affinity Purification, CRAPome.org37). Several
components of well-characterized protein complexes that were enriched with EIF4A2 and
MEPCE are indicated by the colored dots to the right of the heatmaps (See Supplementary
Figs 9-11 for an expanded view). In this and all other heatmaps, values exceeding the Fold
Change (log10) indicated in the color-coding bars are depicted as the maximal intensity
values.
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Figure 3.
Selected biological samples. (a) Schematic representation of the effects of mutations, splice
variants and chemical perturbations on the modulation of specific protein-protein
interactions. In the reference interactome, interaction of the central protein with three
binding partners is represented. If this protein is absent from the cells, all three interactions
are lost (blue interactome; node removal). Interactions can also be selectively lost (green
interactome; edge lost) or gained (red interactome, edge gain). In these cases, the loss/gain
can be absolute (represented here by the presence or absence of an edge), or partial (depicted
by changes in edge width; the magnitude of these changes can be measured by quantitative
proteomics). (b) AP-western validation of a test case for monitoring interactome changes.
FLAG-tagged CDK4 WT and mutant proteins are expressed at similar amounts (to each
other and to the endogenous CDK4 protein) in Flp-In T-REx 293 cells and purified on an
anti-FLAG resin. Association of the endogenous p18INK (CDKN2C) protein was detected
by immunoblotting.
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Figure 4.
Identification of differential interactomes for CDK4 cancer-associated mutants. (a) Principal
component analysis showing the clear separation of two control (FLAG alone) samples and
two CDK4 WT samples in comparison to the two CDK4 R24 samples that show little
separation. (b) Heatmap representation of the proteins passing the confidence threshold in
one of the CDK4 baits relative to the negative controls. The grey cells indicate that the
thresholds for confidence, Fold Change or signal-to-noise were not met in this particular
pairwise comparison (See Supplementary Fig 12 for a global view of all the data without
these missing values and Supplementary Figs 13-14 for expanded views). (c) Schematic of
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the scoring process for differential interactome mapping: in the first step, the potential
interactions for a set of baits are collectively scored against a negative control and proteins
confidently up-regulated with ≥ 1 baits are considered further. In the second step, systematic
pairwise comparisons between all baits, or comparison to a bait used as a reference point,
are performed. (d) Left: Heatmap depicting the high confidence proteins differentially
detected in the R24C and R24H mutants in relation to the WT sample. Only proteins
changing with a confidence ≥ 0.75 and that passed filtering criteria defined in Methods are
depicted. See Supplementary Fig. 15-17 for all pairwise comparisons. Right: Heatmap
showing the iTRAQ ratios of the high confidence SWATH proteins (see Supplementary Fig.
18 for iTRAQ ratio standard deviation). (e) Validation of selected regulated interactions by
AP-western.
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Figure 5.
Use of AP-SWATH to probe drug-modulated interactions. (a) Increased association of
kinase mutants with HSP90 as determined by LUMIER. (b) Heatmap depicting the high
confidence differentially recovered proteins as a consequence of NVP-AUY922 treatment
(all comparisons are pairwise, for the same bait treated with NVP in comparison to the mock
treated sample). See Supplementary Fig. 24 for the heatmap of the first filtering step
(normalization to the negative control) and Fig. 25 for an expanded view). (c) Fold Change
and Median Absolute Variance (error bars) for all proteins from panel. b. See
Supplementary Fig. 26-27 for an expanded view of protein and peptide level changes. (d)
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Fold change of selected proteins in the mutants as compared to the WT following NVP-
AUY922 treatment. (e) Validation of selected regulated interactions by AP-western: 500nM
NVP-AUY922 was used for 1 hour. (f, g) AP-western analysis of time course of CDK4 WT
(f) and R24C mutant (g) dissociation from CDC37-HSP90 in the presence of 100nM NVP-
AUY922. In e, f and g, * indicates the position of the FLAG-tagged bait protein; • indicates
endogenous CDK4.
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